The future role of automation

Home Blog The future role of automation

Share

Following the NHS’ collaboration with Automata, Peter Baker, commercial director at University Hospital Southampton NHS Foundation Trust (UHS), and Craig Johnston, diagnostics and genomics lead at Automata, discuss the impact this will have

10th August 2022Craig Johnston


‘This article has also been published with Building Better Healthcare: ‘The future role of automation

Q. What are the biggest goals for the NHS to achieve in the next few years and how do you hope that automation will help to achieve these goals?

A. Peter Baker: One of the most-exciting challenges for the NHS and UHS is bringing cutting-edge technology to patients and staff, and in doing so attracting global talent into hospitals in order to continue to innovate at the frontline.

UHS has been at the forefront of significant progress over the past few years, including being instrumental in the development of COVID-19 vaccines, and investing in automation technology that supported COVID-19 diagnostic testing. To continue to do this innovative work, attracting talent from different sectors and new geographical areas will be key.

Investing further in automation will also be important to power these advances – and bring in experts who are keen to work with cutting-edge technology.

Moving into genomics is a big focus for us, for example, and one step change in this area will be the automation of screening processes.

To scale work in RNAi, gene expression analysis, or CRISPR fragment analysis, among other genomic applications, reliability and precision is critical – and automation offers this.

We can increase how efficiently research can be carried out, with greater flexibility and throughput in labs and ultimately bring costs down and shorten development cycles.

Q. What role do automation and robotics have to play in laboratories?

A. Craig Johnston: Automation can support laboratories to boost efficiencies by increasing both throughput and the accuracy of experiments and research.

The RT-LAMP testing facility in UHS is a great example of this, as the automated system allowed for thousands of COVID-19 tests to be read daily, with a high level of accuracy.

With the life sciences and biotech industries continuing to advance, automation will also be key to powering innovation.

Emerging areas like synthetic biology and gene editing require close control and precision, and automating processes will be critical to scale while maintaining accuracy and reliability.

Automation and robotics can also help to relieve scientists of repetitive and time-consuming admin tasks by automating entire processes and even whole workflows in labs. This can elevate the scientist’s role by freeing up their valuable time to focus on more-skilled tasks like plate reading and interpretation, enabling them to discover new drugs and bring them to market faster and more effectively.

Automata NHS Southampton
With the life sciences and biotech industries continuing to advance, automation will be key to powering innovation

Q. What trends is Automata seeing from labs and the pharma industry around automating?

A. Craig Johnston: Automation isn’t new for the pharma industry, and we’ve seen it used for tasks like liquid handing and library preparation for a number of years.

Typically, the trend has been towards applying automation to single tools in a lab, and the approach hasn’t always been very flexible.

We’re now seeing the trend start to move towards a more-flexible, modular way of applying automation.

By moving towards what we call a ‘capability-first model’, it’s possible for single automation tools in the lab to perform multiple processes – such as liquid handing or thermocycling – efficiently. In turn, this can make instruments in the lab far more flexible.

The same piece of automation technology can be optimised to carry out new tasks when needed, enabling labs to meet the rising demand for new drugs and medicines. And, as batch sizes become smaller and product lifecycles and time to market become shorter, increasing efficiencies and optimising any automation tools will be critical.

Q. Why did you decide to partner with Automata during the COVID-19 pandemic?

A. Peter Baker: We had a particular need during the pandemic – to be able to process no-swab saliva tests at population scale, against a national scarcity of trained lab technicians. This, of course, created the need for an automated solution for diagnostic testing.

In particular, we liked the fact that Automata’s technology is modular and could be scaled and adapted to our needs within a developing scientific field.

We were looking to quickly turn an office block into an end-to-end production line for processing tests, and this modular approach meant we could be flexible and fit the technology into the space we had.

Beyond that, the partnership we formed with Automata and the way we were able to scale the saliva testing really highlighted how automation could be applied and help in other areas of the hospital too.

Watch Automata’s automation solution at work in the NHS lab.

Author

Share